Roche highlights risk of neuropsychiatric reactions with Lariam

Roche has issued a letter to healthcare professionals reminding them of the risk of serious neuropsychiatric adverse reactions associated with the use of its antimalarial Lariam (mefloquine).

Lariam (mefloquine) is effective for the treatment and prophylaxis of malaria in most parts of the world
Lariam (mefloquine) is effective for the treatment and prophylaxis of malaria in most parts of the world

The most common neuropsychiatric reactions to mefloquine include abnormal dreams, insomnia, anxiety and depression. Hallucinations, psychosis and suicide/suicidal ideation have also been reported. As mefloquine has a long half life, these reactions may be delayed or persist for up to several months after discontinuing treatment.

Start 10 days before entering malarial area

Lariam should now be started 10 days (rather than seven days) before entering the endemic area, to ensure it is well tolerated. If neuropsychiatric reactions occur, Lariam should be discontinued immediately and an alternative antimalarial initiated.

Prescribers should remember that Lariam must not be used for chemoprophylaxis in patients with a psychiatric disorder or a history of such disorders.

View MIMS travel tables

View Lariam drug record

Further information: Roche

Follow MIMS on Twitter

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases